In the FLOW trial, once-weekly semaglutide lowered major kidney disease events by 24% in type 2 diabetes with chronic kidney disease. PICO summary and expert commentary.
Browsing: Type 2 Diabetes
Landmark trials and recent evidence on type 2 diabetes management, glucose-lowering therapy, and outcomes.
A post hoc analysis of the SURPASS-2 phase 3 trial comparing tirzepatide and semaglutide on HOMA2 markers of beta-cell function and insulin sensitivity in type 2 diabetes. PICO summary and expert commentary.
A post hoc analysis of the SURPASS program found tirzepatide produced similar HbA1c, weight, and cardiometabolic improvements whether type 2 diabetes was diagnosed before or after age 40. PICO summary and expert commentary.
STEP-HFpEF DM: once-weekly semaglutide 2.4 mg improved symptoms, weight, and exercise capacity versus placebo in obese, diabetic patients with HFpEF. PICO summary and expert commentary.
A phase 2b trial of the GLP-1/glucagon receptor agonist cotadutide showed dose-dependent reductions in albuminuria in type 2 diabetes with CKD. PICO summary and expert commentary.
A single-center randomized controlled trial testing a cloud-hospital data platform plus dietary management against standard care in 180 adults with type 2 diabetes, reporting a modest 12-week HbA1c advantage. PICO summary and expert commentary.
A post hoc analysis of the SUSTAIN China trial found that the glycaemic efficacy of once-weekly semaglutide versus sitagliptin was consistent across most baseline subgroups. PICO summary and expert commentary.
A phase 1 crossover study of the IcoSema fixed-ratio combination of insulin icodec and semaglutide reports unchanged icodec exposure but a higher, earlier semaglutide peak versus separate injections. PICO summary and expert commentary.
A model-based analysis of a 28-week randomized meal-test substudy comparing tirzepatide 15 mg with semaglutide 1 mg in metformin-treated type 2 diabetes. PICO summary and expert commentary.
Prespecified FLOW subgroup analysis testing whether semaglutide’s kidney and cardiovascular benefits hold with or without baseline SGLT2 inhibitor use. PICO summary and expert commentary.